Cardiovascular and Metabolic Disorders
Overview of the global pharmerging markets
Technavio’s market research analyst predicts the global pharmerging markets to grow steadily at a CAGR of around 13% by 2021. One of the primary drivers for this market is the increasing focus toward biosimilar in potential areas. As most of the patents for originator biologics have expired, the vendors are focusing on the development of duplicate copies of biologics, called biosimilars. These biosimilars provide the same efficacy as that of parent molecule but at a cheaper cost. The availability of cheap manufacturing resources such as land and labor has made the pharmerging market an important option for the development of these biosimilars. For instance, in 2014 trastuzumab, (a biosimilar of CANMab), which is indicated for the treatment of metastatic breast cancer was launched in India. Moreover, the on-going strong market growth in therapeutic areas will contribute further to higher penetration of the pharmerging markets over the next few years.
One of the latest trends gaining traction in this market is the rise in the positive outlook through the adoption of targeted therapies. With the growing incidences of chronic diseases such as cancer, which requires specific therapies for effective treatment, the implementation of targeted therapies is expected to witness substantial upward momentum. Research studies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as
Overview of the global compression therapy market
Technavio’s market research analyst predicts that the global compression therapy market will grow at a CAGR of more than 5% during the forecast period. The emergence of sequential compression therapy systems is anticipated to have a positive influence on the market, due to its growing use in several applications. Sequential calf compression and graduated compression stockings are increasingly being used for prophylaxis in neurosurgery for the prevention of PE and DVT. Also, the intraoperative sequential compression device systems are recommended during prolonged laparoscopic surgery to counter altered venous blood return from the lower extremities and subsequent cardiac depression caused by pneumoperitoneum. Sequential compression is an effective therapy, which generates results within 1-2 hours per day when compared to other alternatives that take 12-48 hours to achieve the same outcome. With an increase in the number of surgical procedures, the chances of developing thromboembolic events, which require treatment using compression therapy systems will also grow, further contributing to the growth of the overall market.
Geographically, the APAC region will witness the fastest growth rate in the global market during the forecast period. Much of the region’s growth can be attributed to the rising incidences of chronic conditions such as diabetes and VTE coupled with recent product innovations. The growing awareness among physicians about new compression systems will bring substantial growth opportunities in the market. Moreover, with the increasing demand for compression therapy in sports applications will further fuel the market growth in the APAC
Overview of the global infantile spasms therapeutics market
The global infantile spasms therapeutics market is anticipated to grow at a steady rate and will post a CAGR of above 2% during the forecast period. One of the primary drivers for this market is the growing scientific advancements in the infantile spasms therapeutic industry. Scientific advancements are helping physicians in early diagnosis, which is a crucial parameter in increasing life expectancy. Accurate diagnosis of infantile spasms can have a significant influence on the physician's decision-making process to prescribe a treatment regimen for individuals. For instance, technological advancements in medical imaging have improved the diagnosis of infantile spasms. Such scientific advantages will help in reducing the undiagnosed population, thereby raising the penetration rate of infantile spasm drugs.
In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The US is the single largest regional market in the infantile spasms drugs market in the Americas. The market is expected to experience steady growth owing to the increasing number of infantile spasms patients in this region. Also, the number of patients diagnosed with infantile spasm is estimated to be nearly half of the total number of patients in the region. To reduce the number of undiagnosed cases the region is witnessing various awareness programs and initiatives. For instance, in the US, the Epilepsy Foundation of Hawaii encouraged its members to dress in purple or a day, to create awareness regarding epilepsy and its related diseases.
Competitive landscape and key vendors
At present, the global infantile spasm therapeutics market is served by a limited number of vendors, this makes the market lucrative and provides immense growth opportunities. The
Overview of the global artificial pancreas devices system market
Market research analysts at Technavio predict that the global artificial pancreas devices system market will grow steadily during the next four years and post an impressive revenue of over USD 1 billion by 2020. The market has witnessed a rapid increase in technological integration, which according to this market research analysis will be one of the primary growth factors for this market. The need for artificial pancreas devices systems to mimic the function of a healthy pancreas will induce vendors to focus on the adoption of advanced technologies. Vendors have already started integrating their artificial pancreas devices systems (APDS) with several sensors, software, and related algorithms to ensure the effective functioning of APDS. For instance, Medtronic has integrated their MiniMed 530G system with SmartGuard Technology, which helps in effectively controlling glucose levels. Additionally, the device is also integrated with the Enlite sensor, which enables the device to monitor glucose levels and take readings at regular intervals and also provide alerts during fluctuations. Such advancements will enable companies to introduce effective artificial pancreas systems, which, in turn, will boost their demand among end-users.
One of the major trends that will gain traction in this market is the increasing demand for remote monitoring applications. The growing need for home healthcare monitoring will drive the need for remote patient monitoring systems in the APDS market as well. This will induce vendors to develop an
Overview of the global next-generation biologics market
According to the market research analysts at Technavio, the next-generation biologics market is anticipated to witness staggering growth and will post a staggering CAGR of more than 14% during the forecast period. The increasing demand for antibody drug conjugates (ADCs) is one of the major factors driving this market’s growth. ADCs are highly effective cytotoxic drugs linked to an mAbs. These drugs have shown to be potent and efficient in treating diseases, including cancers and hematological malignancies. Therefore, in the recent years, antibodies have become the preferred choice to treat respiratory, oncology, and inflammatory diseases. The use of ADCs, including radioimmunotherapy and antibody-directed enzyme prodrug therapy, has increased significantly. The augmented use of these antibodies in drug development increases revenue generation in the global next-generation biologics market, thereby contributing to market growth.
One of the recent trends gaining traction in the market is the emergence of targeted and combination therapies for the treatment of various diseases such as viral infections and cancer. This is mainly because targeted therapies have fewer side effects than conventional non-targeted therapies. Combination therapies work by targeting multiple mechanisms simultaneously. Targeting multiple pathways in diseases such as cancer, reduce the risk of developing treatment-resistant disorders. As a result, combination therapies, which target distinct mechanisms, are highly efficacious in treating various diseases, which will boost this market’s growth over the next four years.
Overview of the autoimmune and inflammatory immunomodulators market
According to the market research analysts at Technavio, the autoimmune and inflammatory immunomodulators market is expected to witness fast-paced growth and will post an impressive CAGR of more than 7% during the predicted period. The development of novel therapies using innovative technologies is one of the major factors driving this market’s growth. The existing drugs in the market do not provide a complete cure for irritable bowel syndrome (IBS) and rheumatoid arthritis. Several research studies have also indicated that nearly one-third of the patients suffering from IBS and undergoing conventional treatment do not respond these drugs. This has led to increased focus on research activities by the vendors with the use of novel technologies for the development of therapies that will provide complete remission of the disease. For instance, Txcell is developing Ovasave by using ASTrIA technology platform for the treatment of IBD such as Crohn’s disease. This technology utilizes antigen-specific Type 1 Treg cells, which recognize the specific antigen at the inflammation site and suppresses the immune responses.
In terms of geography, the Americas led the market and will continue to dominate the market over the coming years. The US was the major revenue contributor and accounted the majority of market shares in the region. The healthcare reforms of various countries are showing a positive impact on the market growth. For example, in the US, the implementation of the Affordable Care Act (ACA) is rapidly changing the business
There is currently intense competition in the cardiovascular and metabolic disorder treatment market. Despite a wide range of drugs available for cardiovascular and metabolic disorders, these conditions remain the leading cause of death in both developed and developing countries, due in part to the rising number of people with sedentary lifestyles globally.
Big players in the pharmaceutical industry are entering the market and focusing on developing innovative compounds for novel targets in order to preserve or restore the physiological functions of patients. Furthermore, pharmaceutical companies are investing significantly in targeted marketing activities.